Skip to content

Immediate and Functional Results of Different Types of Reconstructions After Proximal Gastrectomy For Gastric and Esophagogastric Junction Cancer

Immediate and Functional Results of Different Types of Reconstructions After Proximal Gastrectomy For Gastric and Esophagogastric Junction Cancer

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07441785
Acronym
PROXISTAT
Enrollment
400
Registered
2026-03-02
Start date
2025-01-01
Completion date
2029-06-01
Last updated
2026-04-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric Cancer (GC), Siewert Type II Adenocarcinoma of Esophagogastric Junction, Siewert Type III Adenocarcinoma of Esophagogastric Junction

Keywords

Proximal gastrectomy, Morbidity, Mortality, Quality of life, Surgery, Esophagogastric Junction Cancer

Brief summary

Proximal gastric and esophagogastric junction cancers comprise up to 40% of gastric malignancies. For localized disease, proximal gastrectomy is the main radical procedure, but reconstruction of GI tract often leads to significant functional issues. Rising use of proximal resections and broader indications have increased attention to postoperative quality of life (QoL). Common reconstructions include direct esophagogastrostomy (various types), double-tract reconstruction, jejunal interposition, and newer anti-reflux anastomoses (e.g., double-flap, overlap, tunnel techniques). Each method has unique pros and cons regarding reflux esophagitis, food passage, dumping syndrome, nutritional changes, and long-term QoL. No consensus exists on the optimal technique, leading to variable practices and outcomes. Most research focuses on oncologic radicality and survival, while functional results and QoL remain understudied. Systematic evaluation of functional outcomes across reconstruction types after proximal subtotal gastrectomy is needed in Russian Federation to improve QoL, advance research, and standardize treatment of proximal gastric and EGJ cancers.

Detailed description

Proximal gastric and esophagogastric junction cancer account for up to 40% of all gastric malignancies. For localized disease, proximal gastrectomy remains the primary radical surgical procedure. However, roconstruction of gastrointestinal continuity after this procedure is associated with significant functional disturbances. The increasing frequency of proximal resections and expanding indications have heightened focus on postoperative quality of life (QoL). Currently used reconstruction techniques include direct esophagogastrostomy (in various modifications), double-tract reconstruction, jejunal interposition, and emerging anti-reflux esophagogastric anastomoses (e.g., double-flap technique, single-overlap, tunnel reconstruction, etc). Each method carries distinct advantages and disadvantages concerning reflux esophagitis, food passage, dumping syndrome, nutritional status alterations, and long-term QoL. Despite this variety, no universal consensus exists regarding the optimal reconstruction technique, resulting in heterogeneous surgical practices and variable functional outcomes. Most studies prioritize oncologic radicality and overall survival, whereas functional results and QoL remain under-investigated. To enhance patient QoL, advance research, and standardize treatment of proximal gastric and esophagogastric junction cancers in the Russian Federation, there is a clear need for systematic evaluation of functional outcomes across different reconstruction types following proximal subtotal gastrectomy.

Interventions

Resection of the upper third to one-half of the stomach and the distal portion of the esophagus with different types of digestive system reconstruction

Sponsors

P. Herzen Moscow Oncology Research Institute
Lead SponsorOTHER_GOV
A.Loginov Moscow Clinical Scientific Center
CollaboratorUNKNOWN

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* All consecutive patients with clinically documented primary Gastric or Esophagogastric Junction malignancy (including Siewert I and II) cT1-3N0-2M0 undergoing proximal gastrectomy with curative intent - via open, laparoscopic or robotic approach between 01th January 2025 and 31th December 2026

Exclusion criteria

* Patients with clinical evidence of metastatic disease, including positive peritoneal cytology on a previous staging laparoscopy, or those with known synchronous other cancers. * Esophagogastric Junction Siewert I malignancy * Patients submitted to Emergency surgery or surgery without curative intent * Patients undergoing any other surgery in addition to the curative surgery for primary Esophageal or Esophagogastric Junction malignancy * Patients who have previously undergone surgery on the stomach or colon

Design outcomes

Primary

MeasureTime frameDescription
The structure and frequency of postoperative complications depending on the method of reconstruction, as well as neoadjuvant treatmentwithin 90 days after operationthe types of complication is classified into as follows: esophageal anastomotic leak requiring surgical treatment, esophageal anastomotic leak not requiring surgical treatment, gastric stump necrosis, postoperative bleeding requiring surgical treatment, postoperative bleeding not requiring surgical treatment, postoperative ileum, postoperative pancreatic fistula type B, postoperative pancreatic fistula type C, duodenal stump leak / duodenal stump insufficiency, impaired evacuation from the gastric stump (more than 10 days after surgery), postoperative intestinal perforation or necrosis, persistent air leak through the pleural drain, wound dehiscence (evisceration, hernia), incarcerated diaphragmatic hernia, chylothorax or other types of lymph leakage, infectious complications of the postoperative wound, other complications requiring repeat intervention or another invasive procedure, other.
Overall survival1 year after operationOverall survival within 1 year after operation
Frequency of local recurrence1 year after operationFrequency of local recurrence within 1 year after operation
Frequency of tumor progression1 year after operationFrequency of tumor progression within 1 year after operation

Secondary

MeasureTime frameDescription
Incidence of development and the severity of reflux esophagitis6 and 12 months after surgeryIncidence of development and the severity (degree of expression) of reflux esophagitis according to the Los Angeles classification in the postoperative period
Incidence of development of esophageal anastomotic stricture6 and 12 months after surgeryIncidence of development of esophageal anastomotic stricture in the postoperative period.
Incidence and severity of dumping syndrome6 and 12 months after surgeryIncidence and severity of dumping syndrome, along with quality of life assessment in the postoperative period according to the KOQUSS-40 questionnaire at 6 and 12 months postoperatively
Pressure of the esophageal anastomosis6 and 12 months after surgeryPressure of the esophageal anastomosis in the postoperative period according to esophageal manometry
The level of body weight reduction6 and 12 months after surgeryThe level of body weight reduction in the postoperative period
The level of hemoglobin6 and 12 months after surgeryThe level of hemoglobin in 6 and 12 months after surgery
Food passage rate through the esophagus and the stump of the stomach6 and 12 months after surgeryThe rate of passage of food through the esophagus and the stump of the stomach, as well as evacuation from the stump of the stomach into the small intestine based on scintigraphy of the stomach and esophagus after 12 months after surgery

Countries

Russia

Contacts

CONTACTAndrey Ryabov, MD, PhD
ryabovdoc@mail.ru+7 (495) 150-11-22
STUDY_DIRECTORAndrey Ryabov, MD, PhD

P.Herzen Moscow Oncological Research Institute

PRINCIPAL_INVESTIGATORVladimir Khomyakov, MD, PhD

P.Herzen Moscow Oncological Research Institute

PRINCIPAL_INVESTIGATORNuriddin Abdulkhakimov, PhD

P.Herzen Moscow Oncological Research Institute

PRINCIPAL_INVESTIGATORPavel Smirnov

P.Herzen Moscow Oncological Research Institute

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 23, 2026